PMID- 12933867
OWN - NLM
STAT- MEDLINE
DCOM- 20030929
LR  - 20210526
IS  - 0019-9567 (Print)
IS  - 1098-5522 (Electronic)
IS  - 0019-9567 (Linking)
VI  - 71
IP  - 9
DP  - 2003 Sep
TI  - Gastric Helicobacter infection inhibits development of oral tolerance to food 
      antigens in mice.
PG  - 5219-24
AB  - The increase in the transcellular passage of intact antigens across the digestive 
      epithelium infected with Helicobacter pylori may interfere with the regulation of 
      mucosal immune responses. The aim of this work was to study the capacity of 
      Helicobacter infection to inhibit the development of oral tolerance or to promote 
      allergic sensitization and the capacity of a gastro-protective agent, rebamipide, 
      to interfere with these processes in mice. Oral tolerance to ovalbumin (OVA) was 
      studied in 48 C3H/He 4-week-old mice divided into four groups: (i) OVA-sensitized 
      mice; (ii) OVA-"tolerized" mice (that is, mice that were rendered immunologically 
      tolerant); (iii) H. felis-infected, OVA-tolerized mice; (iv) and H. 
      felis-infected, OVA-tolerized, rebamipide-treated mice. Oral sensitization to hen 
      egg lysozyme (HEL) was studied in 48 mice divided into four groups: (i) controls; 
      (ii) HEL-sensitized mice; (iii) H. felis-infected, HEL-sensitized mice; and (iv) 
      H. felis-infected, HEL-sensitized, rebamipide-treated mice. Specific anti-OVA or 
      anti-HEL immunoglobulin E (IgE) and IgG1/IgG2a serum titers were measured by 
      enzyme-linked immunosorbent assay. Additionally, the capacity of rebamipide to 
      interfere with antigen presentation and T-cell activation in vitro, as well as 
      absorption of rebamipide across the epithelial monolayer, was tested. H. felis 
      infection led to the inhibition of oral tolerance to OVA, but rebamipide 
      prevented this inhibitive effect of H. felis. H. felis infection did not enhance 
      the sensitization to HEL, but rebamipide inhibited the development of this 
      sensitization. Moreover, rebamipide inhibited in a dose-dependent manner antigen 
      presentation and T-cell activation in vitro and was shown to be able to cross the 
      epithelium at a concentration capable of inducing this inhibitory effect. We 
      conclude that H. felis can inhibit the development of oral tolerance to OVA in 
      mice and that this inhibition is prevented by rebamipide.
FAU - Matysiak-Budnik, Tamara
AU  - Matysiak-Budnik T
AD  - INSERM EMI-0212, Faculte de Medecine Necker-Enfants Malades, Paris, France.
FAU - van Niel, Guillaume
AU  - van Niel G
FAU - Megraud, Francis
AU  - Megraud F
FAU - Mayo, Kathryn
AU  - Mayo K
FAU - Bevilacqua, Claudia
AU  - Bevilacqua C
FAU - Gaboriau-Routhiau, Valerie
AU  - Gaboriau-Routhiau V
FAU - Moreau, Marie-Christiane
AU  - Moreau MC
FAU - Heyman, Martine
AU  - Heyman M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Infect Immun
JT  - Infection and immunity
JID - 0246127
RN  - 0 (Antigens)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Quinolones)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 9006-59-1 (Ovalbumin)
RN  - EC 3.2.1.17 (Muramidase)
RN  - LR583V32ZR (rebamipide)
RN  - OF5P57N2ZX (Alanine)
SB  - IM
MH  - Administration, Oral
MH  - Alanine/*analogs & derivatives/pharmacology
MH  - Anaphylaxis/etiology
MH  - Animals
MH  - Antigen Presentation/drug effects
MH  - Antigens/administration & dosage
MH  - Chickens
MH  - Female
MH  - Gastritis/*immunology
MH  - Helicobacter Infections/*immunology
MH  - Immune Tolerance
MH  - Immunity, Mucosal
MH  - Immunoglobulin E/biosynthesis
MH  - Immunoglobulin G/biosynthesis
MH  - In Vitro Techniques
MH  - Intestines/drug effects/immunology
MH  - Mice
MH  - Mice, Inbred C3H
MH  - Muramidase/immunology
MH  - Ovalbumin/administration & dosage/immunology
MH  - Quinolones/pharmacology
MH  - T-Lymphocytes/drug effects/immunology
PMC - PMC187370
EDAT- 2003/08/23 05:00
MHDA- 2003/09/30 05:00
PMCR- 2003/09/01
CRDT- 2003/08/23 05:00
PHST- 2003/08/23 05:00 [pubmed]
PHST- 2003/09/30 05:00 [medline]
PHST- 2003/08/23 05:00 [entrez]
PHST- 2003/09/01 00:00 [pmc-release]
AID - 1837 [pii]
AID - 10.1128/IAI.71.9.5219-5224.2003 [doi]
PST - ppublish
SO  - Infect Immun. 2003 Sep;71(9):5219-24. doi: 10.1128/IAI.71.9.5219-5224.2003.